dr. mesa gives an overview of upcoming trials in myelofibrosis
Published 11 years ago • 120 plays • Length 1:36Download video MP4
Download video MP3
Similar videos
-
1:33
dr. mesa on late-stage trials in myelofibrosis
-
55:50
drs. mesa, jamieson, & mascarenhas discuss #myelofibrosis during #asco23 - https://bit.ly/45niv2g
-
1:00:56
taking the targeted option for myelofibrosis
-
1:23:15
drs.verstovsek & mesa discuss latest myelofibrosis updates from #soho2021: https://bit.ly/3hfp1kc
-
1:54
dr. mesa discusses jak inhibitors for myelofibrosis
-
2:22
dr. mesa on the evolving role of jak2 inhibitors in myelofibrosis
-
4:14
stepping forward: future treatment of myelofibrosis
-
51:55
ruben mesa, md, ut health san antonio
-
1:23
dr. tal zaks on treatments and pathways in myelofibrosis
-
1:14
dr. mesa on the emergence of jak inhibitors in myelofibrosis
-
1:14
dr. mesa on the safety profiles of jak inhibitors in myelofibrosis
-
0:46
safety of treating myelofibrosis with ruxolitinib – results from jump trial
-
1:15
ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis
-
1:10
fedratinib reemerges as fda-approved treatment of myelofibrosis
-
3:20
comfort: five-year outcomes of ruxolitinib in patients with myelofibrosis
-
1:51
improving outcomes for myelofibrosis
-
1:39
upcoming agents in et and pv
-
25:13
update on jak inhibitors for myelofibrosis: there is more than one
-
1:10
dr. ruben mesa on comfort-1 for myelofibrosis